Preclinical CD69 immuno-PET using 89Zr-DFO-CD69 Ab was found to be highly sensitive for the detection of the anti-GBM immune response and served as a predictor of prognosis upon ICI therapy. This evidence concerns the gene CD69 and glioblastoma.